✦ LIBER ✦

Treatment of poor-risk myelodysplastic syndromes and acute myeloid leukemia with a combination of 5-azacytidine and valproic acid

✍ Scribed by Andrea Kuendgen; Gesine Bug; Oliver G. Ottmann; Detlef Haase; Julie Schanz; Barbara Hildebrandt; Kathrin Nachtkamp; Judith Neukirchen; Ariane Dienst; Rainer Haas; Ulrich Germing; Norbert Gattermann

Book ID: 107687374
Publisher: Springer-Verlag
Year: 2011
Tongue: English
Weight: 195 KB
Volume: 2
Category: Article
ISSN: 1868-7075
DOI: 10.1007/s13148-011-0031-9

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Combination of 5-azacytidine and thalido

Combination of 5-azacytidine and thalidomide for the treatment of myelodysplastic syndromes and acute myeloid leukemia

✍ Azra Raza; Murtaza Mehdi; Muhammad Mumtaz; Fahad Ali; Steven Lascher; Naomi Gali 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 224 KB 👁 1 views

## Abstract ## BACKGROUND. The treatment of myelodysplastic syndromes (MDS) remains a challenge to the clinician despite recent advances. Many patients will either not respond or will have only limited and/or brief responses to single‐agent therapy. Eventually, 30% of patients with MDS will progre

Increase in platelet count in older, poo

Increase in platelet count in older, poor-risk patients with acute myeloid leukemia or myelodysplastic syndrome treated with valproic acid and all-trans retinoic acid

✍ Chiara Pilatrino; Daniela Cilloni; Emanuela Messa; Alessandro Morotti; Emilia Gi 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 772 KB

Clinical trial of valproic acid and all-

Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemia

✍ Gesine Bug; Markus Ritter; Barbara Wassmann; Claudia Schoch; Thorsten Heinzel; K 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 275 KB 👁 2 views

## Abstract ## BACKGROUND Valproic acid (VPA), a histone deacetylase (HDAC) inhibitor, induced in vitro differentiation of primary acute myeloid leukemia (AML) blasts, an effect enhanced by all‐trans retinoic acid (ATRA). Clinical responses to VPA were recently observed in patients with myelodyspl

Pilot study of combination transcription

Pilot study of combination transcriptional modulation therapy with sodium phenylbutyrate and 5-azacytidine in patients with acute myeloid leukemia or myelodysplastic syndrome

✍ Maslak, P; Chanel, S; Camacho, L H; Soignet, S; Pandolfi, P P; Guernah, I; Warre 📂 Article 📅 2005 🏛 Nature Publishing Group 🌐 English ⚖ 120 KB

Combination decitabine, arsenic trioxide

Combination decitabine, arsenic trioxide, and ascorbic acid for the treatment of myelodysplastic syndrome and acute myeloid leukemia: A phase I study

✍ John S. Welch; Jeffery M. Klco; Feng Gao; Elizabeth Procknow; Geoffery L. Uy; Ke 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 774 KB

Childhood immune thrombocytopenia (ITP) has a favorable outcome in most cases but severe bleeding may occur, mostly in children with very low platelet counts. Although first-line therapies are well defined, management of refractory ITP is not consensual. Vinblastine (VBL) is one second-line treatmen

Results of a phase 2 study of valproic a

Results of a phase 2 study of valproic acid alone or in combination with all-transretinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemia

✍ Andrea Kuendgen; Sabine Knipp; Frank Fox; Corinna Strupp; Barbara Hildebrandt; C 📂 Article 📅 2005 🏛 Springer 🌐 English ⚖ 97 KB